Key Developments: Genomma Lab Internacional SAB de CV (LABB.MX)

LABB.MX on Mexico Stock Exchange

28.19MXN
11:29am EST
Price Change (% chg)

$0.21 (+0.75%)
Prev Close
$27.98
Open
$28.00
Day's High
$28.22
Day's Low
$27.89
Volume
79,056
Avg. Vol
3,183,915
52-wk High
$37.15
52-wk Low
$23.80

Search Stocks

Latest Key Developments (Source: Significant Developments)

Genomma Lab Internacional places bonds
Friday, 28 Nov 2014 07:27am EST 

Genomma Lab Internacional SAB de CV:Says it has placed bonds in amount of 1,500 million pesos.Maturity five years and two months, in Jan. 2020.Rate TIIE 28 days plus 0.60 percentage points.Underwriters participating jointly in the offer were Casa de Bolsa SantanderSA de CV, Grupo Financiero Santander Mexico y Casa de Bolsa BBVA Bancomer SA de CV and Grupo Financiero BBVA Bancomer.  Full Article

HR Ratings changes outlook of Genomma Lab Internacional to positive; affirms long-term rating
Friday, 11 Jul 2014 10:07am EDT 

Genomma Lab Internacional SAB de CV:HR Ratings has affirmed its long-term credit rating on company at HR AA and changed outlook to positive from stable.  Full Article

Genomma Lab Internacional closes acquisition of 50 pct stake in Grupo Comercial e Industrial Marzam
Monday, 30 Jun 2014 08:16am EDT 

Genomma Lab Internacional SAB de CV:Closes acquisition of 50 percent stake in Grupo Comercial e Industrial Marzam SA de CV.Transaction price 600 million pesos.Genomma has option to acquire 100 percent of Grupo Marzam till end of 2016.  Full Article

Genomma Lab Internacional SAB de CV to acquire 50 percent stake in Grupo Comercial e Industrial Marzam SA de CV
Sunday, 9 Mar 2014 08:00pm EDT 

Genomma Lab Internacional SAB de CV:Signs an agreement to acquire a 50 percent stake of Grupo Comercial e Industrial Marzam SA de CV with an option to acquire a 100 percent of the company.Says that once approved the transaction, the price of the acquired stake will amount to 600 million Mexican Pesos.  Full Article

Fitch affirms its credit ratings on Genomma Lab Internacional SAB de CV
Friday, 21 Feb 2014 04:35pm EST 

Genomma Lab Internacional SAB de CV:Says Fitch Ratings has affirmed its national long and short-term ratings at AA(mex) and F1+(mex), respectively.The outlook is stable.  Full Article

HR Ratings affirms HR AA rating on Genomma Lab Internacional SAB de CV
Thursday, 30 Jan 2014 01:05pm EST 

Genomma Lab Internacional SAB de CV:Says HR Ratings has affirmed its long-term rating on the company at HR AA.Says the outlook is stable.Says the rating action follows the company's announcement on the acquisition of two packages of OTC drug brands.  Full Article

Genomma Lab Internacional SAB de CV gives FY 2014 earnings guidance and international expansion strategy
Sunday, 12 Jan 2014 07:00pm EST 

Genomma Lab Internacional SAB de CV:Announces its 2014 earnings guidance and international expansion strategy, focused mainly on the Brazilian market.Says for 2014 the company has taken conservative approach regarding its guidance, estimating a consolidated net sales growth of at least 15 percent and an EBITDA margin of more than 26.5 percent, while maintaining its focus on free cash flow generation.Says growth will be mainly based on further consolidation of the company within the international markets.Says as part of the strategic international expansion plans, mainly in Brazil as well as in other Latin-American countries, it has acquired two packages of OTC brands for a multiple of 3.4 times sales, which is equivalent to an amount of 1,620 million pesos.Says the first package of brands was acquired from McNEIL-PPC Inc, and includes the brands: Agarol, Kaopectate, Masse, Triatop, Emplastro Sabia, Bebederm, Carlo Erba and Dulcoryl, which have presence in Brazil, Mexico, Colombia, Ecuador, Peru, Panama, Guatemala, Honduras, El Salvador and Uruguay.Says through the second package, the company has acquired the right to acquire 15 brands and 30 sanitary registrations of OTC products in Brazil in the anti-flu drugs, anti-acids, anti-micotics and multi-vitamins categories, among others.  Full Article

Genomma Lab Internacional SAB de CV Announces Bonds Issuance
Wednesday, 2 Oct 2013 03:50pm EDT 

Genomma Lab Internacional SAB de CV announced the Second Issuance of Bonds (Certificados Bursatiles) in the amount of up to MXN 2,000,000,000, under the Program in the total amount of up to MXN 8,000,000,000, at a nominal value of MXN 100 per bond for up to 20,000,000 bonds, with a reference rate of TIIE 28 days, and with a maturity on September 28, 2017.  Full Article

Genomma Lab Internacional SAB de CV Includes Seven Brands Into Its Portfolio
Friday, 27 Sep 2013 09:49am EDT 

Genomma Lab Internacional SAB de CV announced that it has signed diverse acquisition contracts and licenses agreements for the use of such brands as: Oxigricol, with Representaciones e Investigaciones Medicas; Mopral, Xyloproct and Xyloderm, with AstraZeneca; Estomacurol, with Laboratorios Imperiales, and Passiflorine y Ah- Micol, with Laboratorios Columbia Comercial. Consequently, the Company has consolidated its presence in the OTC market. The transaction amounts to MXN 252.1 million.  Full Article

Genomma Lab Internacional SAB de CV Announces Bonds Issuance
Thursday, 4 Jul 2013 09:19am EDT 

Genomma Lab Internacional SAB de CV announced the First Issuance of Bonds (Certificados Bursatiles) in the amount of up to MXN 2,000,000,000, under the Program in the total amount of up to MXN 8,000,000,000, at a nominal value of MXN 100 per bond for up to 20,000,000 bonds, with a reference rate of TIIE 28 days, and with a maturity on July 2, 2018.  Full Article

Search Stocks